Join our newsletter
Get updated info, tips and news about breastfeeding, e-lactancia project and other initiatives from APILAM
Legitimation: Consent of the interested party
As a user and interested I inform you that the data you provide will be located on the servers of MailChimp (email marketing provider of APILAM) outside the EU in the USA. MailChimp is covered by the EU-US Privacy Shield agreement, whose information is available here, approved by the European Committee for Data Protection. See Mailchimp's privacy policy. (https://mailchimp.com/legal/privacy/).
The fact that you do not enter the personal data that appear on the form as mandatory may have the consequence that we can not meet your request.
You can exercise your rights of access, rectification, limitation and delete the data in apilam.es@gmail.com as well as the right to file a claim with a control authority.
You can consult the additional and detailed information on Data Protection on this website: http://e-lactancia.org, as well as consult our own privacy policy.
Levosimendan is a calcium sensitizer, cardiac inotrope and vasodilator, indicated to treat acute decompensation of heart failure. It is administered as an intravenous infusion for 24 hours.
At the time of the last update, we found no published data on its excretion in breast milk.
Its low molecular weight and the low fixation of its active metabolites to plasma proteins, suggest that its excretion in breast milk could be significant, in fact, in a treated mother levosimendan was not found in breast milk, but its active metabolite OR-1896 was found in a measurable amount: 0.1 ng/mL. (Benlolo 2004)
Until further published data on this drug in relation to lactation are known, safer alternatives are preferable. (Kearney 2018)
It is advisable to wait at least 5 ½ T (5 x 80 = 400 hours: 16 days) before resuming breastfeeding, to ensure the elimination of the active metabolite of levosimendan from the organism, as indicated by the manufacturer. (AEMPS 2021)